• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >State of the Art Microbiological Monitoring in the Pharmaceutical Industry: Translational Opportunities.
【24h】

State of the Art Microbiological Monitoring in the Pharmaceutical Industry: Translational Opportunities.

机译：制药行业最先进的微生物监测：转化机会。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Microbiological testing plays an ever increasing role in delivering high quality drug products to patients, whether it's practiced in the pharmaceutical laboratory and in the manufacturing environment. In response to the drive for continuous improvement and further economies, a variety of new methodologies have emerged in recent years which automate existing methods, make use of surrogate markers for growth, or are based on wholly new technologies. These new methodologies offer significant improvements in terms of the speed, accuracy, precision and specificity with which testing can be performed. However, in spite of the limitations of current culture methods, acceptance of new and potentially superior methods has only started to gain momentum within the pharmaceutical, biotechnology and medical device industries. We believe this continues to be due in part to a lack of clear guidance regarding the demonstration of their equivalence to existing methods acceptable to regulatory agencies and validation of the equipment associated with the new methods. In any case, many of these new rapid methods may have a role to play in other applications including missions in space where we want to know the impact of microorganisms on space travel, as well as what microorganisms might be waiting to be discovered.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号